Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 27 | 2023 | 2887 | 2.640 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2019 | 2270 | 1.760 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2017 | 2356 | 0.820 |
Why?
|
| Genetic Loci | 3 | 2016 | 250 | 0.810 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2023 | 137 | 0.670 |
Why?
|
| Estrogen Receptor alpha | 3 | 2017 | 144 | 0.670 |
Why?
|
| Germ-Line Mutation | 4 | 2019 | 329 | 0.650 |
Why?
|
| BRCA1 Protein | 7 | 2019 | 200 | 0.640 |
Why?
|
| Mutation | 9 | 2023 | 3967 | 0.630 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 9 | 0.620 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 64 | 0.600 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 182 | 0.560 |
Why?
|
| Vitamin D | 1 | 2017 | 261 | 0.520 |
Why?
|
| BRCA2 Protein | 5 | 2019 | 158 | 0.510 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 25 | 0.430 |
Why?
|
| Glypicans | 1 | 2012 | 6 | 0.420 |
Why?
|
| Genetic Testing | 3 | 2018 | 535 | 0.420 |
Why?
|
| Microsatellite Repeats | 1 | 2012 | 144 | 0.420 |
Why?
|
| Genome-Wide Association Study | 5 | 2023 | 1620 | 0.420 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 113 | 0.410 |
Why?
|
| Nigeria | 7 | 2018 | 152 | 0.410 |
Why?
|
| Telomerase | 1 | 2011 | 55 | 0.410 |
Why?
|
| Genetic Association Studies | 6 | 2017 | 294 | 0.400 |
Why?
|
| Female | 32 | 2023 | 44507 | 0.400 |
Why?
|
| Mass Screening | 2 | 2018 | 617 | 0.390 |
Why?
|
| Gene Fusion | 1 | 2010 | 38 | 0.380 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1464 | 0.360 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 279 | 0.350 |
Why?
|
| Case-Control Studies | 8 | 2019 | 1804 | 0.350 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 302 | 0.340 |
Why?
|
| Genotype | 6 | 2023 | 1850 | 0.340 |
Why?
|
| Middle Aged | 18 | 2023 | 25017 | 0.340 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1208 | 0.340 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 532 | 0.320 |
Why?
|
| Alleles | 4 | 2017 | 1127 | 0.320 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 744 | 0.320 |
Why?
|
| Carcinoma | 1 | 2011 | 436 | 0.310 |
Why?
|
| Adult | 16 | 2019 | 25640 | 0.290 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 696 | 0.290 |
Why?
|
| Humans | 33 | 2023 | 86601 | 0.280 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1196 | 0.260 |
Why?
|
| Up-Regulation | 2 | 2018 | 712 | 0.260 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1169 | 0.250 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 526 | 0.240 |
Why?
|
| Gene Frequency | 3 | 2016 | 677 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2016 | 628 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 111 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2016 | 534 | 0.200 |
Why?
|
| Risk | 2 | 2012 | 674 | 0.180 |
Why?
|
| Epigenesis, Genetic | 3 | 2018 | 479 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2261 | 0.170 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2018 | 9 | 0.170 |
Why?
|
| CpG Islands | 2 | 2016 | 151 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1384 | 0.170 |
Why?
|
| Homologous Recombination | 1 | 2018 | 51 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 853 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 102 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 54 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3352 | 0.150 |
Why?
|
| Ribonuclease III | 1 | 2016 | 14 | 0.140 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 167 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 937 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2017 | 195 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 392 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2013 | 678 | 0.120 |
Why?
|
| Genomics | 1 | 2019 | 720 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 28 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2013 | 79 | 0.110 |
Why?
|
| Base Sequence | 3 | 2012 | 2330 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 217 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2013 | 229 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 125 | 0.110 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 10 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2426 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 1197 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2011 | 13 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 41 | 0.100 |
Why?
|
| Logistic Models | 2 | 2013 | 1185 | 0.100 |
Why?
|
| China | 1 | 2012 | 228 | 0.100 |
Why?
|
| Family Health | 1 | 2011 | 162 | 0.100 |
Why?
|
| Ataxin-7 | 1 | 2010 | 5 | 0.100 |
Why?
|
| Heredity | 1 | 2010 | 19 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2011 | 270 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 160 | 0.090 |
Why?
|
| Breast Neoplasms, Male | 1 | 2010 | 30 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2023 | 25 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 207 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 192 | 0.090 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 473 | 0.090 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1074 | 0.090 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 170 | 0.090 |
Why?
|
| Haplotypes | 1 | 2011 | 642 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 999 | 0.080 |
Why?
|
| Risk Factors | 6 | 2016 | 5416 | 0.080 |
Why?
|
| Poly A | 1 | 2008 | 23 | 0.080 |
Why?
|
| Pedigree | 1 | 2010 | 966 | 0.080 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 171 | 0.080 |
Why?
|
| Smoking | 1 | 2012 | 609 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 503 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 3241 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2023 | 2767 | 0.070 |
Why?
|
| Chicago | 1 | 2010 | 1379 | 0.070 |
Why?
|
| Aged | 4 | 2019 | 18402 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 456 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 1239 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1373 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 162 | 0.050 |
Why?
|
| Breast | 1 | 2023 | 286 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1981 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 317 | 0.050 |
Why?
|
| Cameroon | 1 | 2019 | 14 | 0.050 |
Why?
|
| Uganda | 1 | 2019 | 34 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 53 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 395 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 96 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 56 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 76 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 857 | 0.040 |
Why?
|
| Exome | 1 | 2018 | 127 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 151 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 4210 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 223 | 0.040 |
Why?
|
| High Mobility Group Proteins | 1 | 2016 | 26 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2018 | 458 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 106 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 3030 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 381 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 370 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 199 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2018 | 394 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 260 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 461 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 384 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1538 | 0.030 |
Why?
|
| Male | 3 | 2012 | 40956 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1161 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1313 | 0.030 |
Why?
|
| Prognosis | 2 | 2012 | 3674 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 504 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 310 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 128 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2016 | 429 | 0.030 |
Why?
|
| Premenopause | 1 | 2013 | 54 | 0.030 |
Why?
|
| Parity | 1 | 2013 | 93 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1937 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2377 | 0.030 |
Why?
|
| Barbados | 1 | 2012 | 7 | 0.030 |
Why?
|
| Apoptosis | 1 | 2019 | 1683 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2013 | 135 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2012 | 48 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 265 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 15 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 770 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2010 | 205 | 0.020 |
Why?
|
| Introns | 1 | 2010 | 289 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 11352 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2008 | 35 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 450 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 92 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 927 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1860 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 281 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 498 | 0.020 |
Why?
|
| Histones | 1 | 2008 | 311 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 2893 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 689 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6501 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3636 | 0.020 |
Why?
|
| Gene Expression | 1 | 2008 | 1284 | 0.010 |
Why?
|
| Genome, Human | 1 | 2008 | 756 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 26581 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 926 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2261 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 5974 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1749 | 0.010 |
Why?
|